Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 2/2019

24.01.2019 | Editorial

Impact of FAAH gene, hyperactivation in emotion processing brain regions and Lavender oil preparation Silexan in anxiety

verfasst von: Kenji Hashimoto

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Excerpt

Growing evidence suggests that the endogenous cannabinoid system plays a role in normal emotional processing, specifically in the anxiety and stress response, and in affective disorders such as anxiety disorder and depression [1]. There are several lines of evidence suggesting either therapeutic potential or harmful effects associated with cannabis use in psychiatric disorders [2]. The integral enzyme fatty acid amide hydrolase (FAAH) is a catabolic enzyme and primary regulator anandamide signaling in the brain. The single nucleotide polymorphism in the human FAAH gene results in a missense mutation (385C to A) that converts a conserved proline residue to threonine (Pro129 to Thr), producing a FAAH variant that displays normal catalytic properties but an enhanced sensitivity to proteolytic degradation [3], resulting in the decreased expression of FAAH protein and enzymatic activity as well as increased anandamide levels in the brain. Thus, it is likely that genetic mutations in FAAH gene may support a potential link between functional abnormalities in the endogenous cannabinoid system and cannabis abuse. In this issue, the A-allele carriers in the FAAH gene in healthy young adults (n = 48) show stronger fronto-amygdala connectivity during rest [4]. In addition, exploratory whole-brain analyses show differential functional activity of A- allele carriers during emotion reactivity and emotion regulation. This preliminary study suggests a link between FAAH C385A and fronto-amygdala connectivity during rest, and provides a finding for differential functional activity during emotion reactivity and emotion regulation depending on FAAH genotypes. Further study using a large sample size of patients with anxiety disorder is needed to confirm the role of FAAH C385A gene in emotion processing or anxiety disorders. …
Literatur
1.
Zurück zum Zitat Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A (2017) The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev 76(Pt A):56–66CrossRefPubMedPubMedCentral Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A (2017) The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev 76(Pt A):56–66CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Sipe JC1, Chiang K, Gerber AL, Beutler E, Cravatt BF (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99:8394–8399CrossRefPubMed Sipe JC1, Chiang K, Gerber AL, Beutler E, Cravatt BF (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99:8394–8399CrossRefPubMed
5.
Zurück zum Zitat Witthöft M, Kerstner T, Ofer J, Mier D, Rist F, Diener C, Bailer J (2016) Cognitive biases in pathological health anxiety: the contribution of attention, memory, and evaluation processes. Clin Psychol Sci 4:464–479CrossRef Witthöft M, Kerstner T, Ofer J, Mier D, Rist F, Diener C, Bailer J (2016) Cognitive biases in pathological health anxiety: the contribution of attention, memory, and evaluation processes. Clin Psychol Sci 4:464–479CrossRef
7.
Zurück zum Zitat Haller H, Cramer H, Lauche R, Gass F, Dobos GJ (2014) The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry 14:128CrossRefPubMedPubMedCentral Haller H, Cramer H, Lauche R, Gass F, Dobos GJ (2014) The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry 14:128CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kasper S, Müller WE, Volz HP, Möller HJ, Koch E, Dienel A (2018) Silexan in anxiety disorders: clinical data and pharmacological background. World J Biol Psychiatry 19:412–420CrossRefPubMed Kasper S, Müller WE, Volz HP, Möller HJ, Koch E, Dienel A (2018) Silexan in anxiety disorders: clinical data and pharmacological background. World J Biol Psychiatry 19:412–420CrossRefPubMed
9.
Zurück zum Zitat Kasper S, Gastpar M, Müller WE, Volz HP (2010) Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25:277–287CrossRefPubMed Kasper S, Gastpar M, Müller WE, Volz HP (2010) Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25:277–287CrossRefPubMed
Metadaten
Titel
Impact of FAAH gene, hyperactivation in emotion processing brain regions and Lavender oil preparation Silexan in anxiety
verfasst von
Kenji Hashimoto
Publikationsdatum
24.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 2/2019
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-019-00987-1

Weitere Artikel der Ausgabe 2/2019

European Archives of Psychiatry and Clinical Neuroscience 2/2019 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.